Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 5/20 | 0.46 |
| ▸ | JUN | P05412 | 3/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.46 |
| ▸ | RELA | Q04206 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.40 |
| ▸ | XPO1 | O14980 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | CRHBP | P24387 | 1/20 | 0.39 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ASPH | Q12797 | 1/20 | 0.38 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.38 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.38 |
| ▸ | ATF1 | P18846 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7754141 | 0.98 | KEAP1 (0.46) | KEAP1NFE2L2NFKB1JUNNFKB2 | |
| Ethylene SCHEMBL29153723 | 0.96 | NFKB1 (0.44) | KEAP1NFE2L2NFKB1JUNNFKB2 | |
| Dimethylformamide SCHEMBL27816337 | 0.86 | HPGD (0.41) | KEAP1NFE2L2NFKB1JUNNFKB2 | |
| SCHEMBL429969 | 0.83 | NFKB1 (0.46) | KEAP1NFE2L2NFKB1JUNNFKB2 | |
| SCHEMBL31469871 | 0.83 | NFKB1 (0.46) | KEAP1NFE2L2NFKB1JUNNFKB2 | |
| SCHEMBL914000 | 0.81 | NFKB1 (0.45) | NFKB1JUNNFKB2RELALMNA | |
| SCHEMBL1320432 | 0.81 | NFKB1 (0.49) | NFKB1JUNNFKB2RELALMNA | |
| SCHEMBL29724129 | 0.81 | NFKB1 (0.45) | NFKB1JUNNFKB2RELALMNA | |
| SCHEMBL8738488 | 0.81 | KEAP1 (0.46) | KEAP1NFE2L2LMNASMN1; SMN2HPGD | |
| SCHEMBL14637332 | 0.81 | KEAP1 (0.46) | KEAP1NFE2L2LMNASMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 189 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4444293-A2 | METHODS OF PREPARING SUBSTITUTED PYRAZOLOPYRIMIDINES | KSQ Therapeutics, Inc. (US) | 2024-10-16 | — | — | EP | claimed |
| CN-118369094-A | Process for preparing substituted pyrazolopyrimidines | KSQ治疗公司 | 2024-07-19 | — | — | CN | claimed |
| WO-2023108048-A2 | METHODS OF PREPARING SUBSTITUTED PYRAZOLOPYRIMIDINES | KSQ Therapeutics, Inc. (US) | 2023-06-15 | — | — | WO | claimed |
| CN-112592318-A | 2- (4-methionyl) anilino-4-aminopyrimidine derivatives and application thereof | 贵州医科大学 | 2021-04-02 | — | — | CN | claimed |
| US-12509441-B2 | Compounds used as kinase inhibitors and application thereof | TYK MEDICINES (ZHENGZHOU), INC. (CN) | 2025-12-30 | — | — | US | disclosed |
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-26 | — | — | US | disclosed |
| US-20250115597-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO LTD (CN) | 2025-04-10 | — | — | US | disclosed |
| WO-2025049481-A1 | METHODS OF EDITING AN HLA-A GENE IN VITRO | INTELLIA THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| CN-119285628-A | Compounds for the treatment and prophylaxis of respiratory syncytial virus infection diseases | 石药集团中奇制药技术（石家庄）有限公司 | 2025-01-10 | — | — | CN | disclosed |
| US-12168009-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-12-17 | — | — | US | disclosed |
| US-12129250-B2 | TYK2 inhibitors and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-10-29 | — | — | US | disclosed |
| US-12129237-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2024-10-29 | — | — | US | disclosed |
| US-4534908-A | Water-soluble disazo compounds and new bis-(aminophenoxy)-ethane compounds having fiber-reactive groups as the tetrazo components, and use of the disazo compounds as dyestuffs | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-08-13 | — | — | US | disclosed |
| EP-0071168-B1 | WATER-SOLUBLE DISAZO COMPOUNDS AND BIS-(AMINO-PHENOXY)-ETHANE COMPOUNDS WITH FIBRE REACTIVE GROUPS AS TETRAZO COMPOUNDS, PROCESS FOR THE PREPARATION OF THESE COMPOUNDS AND THE USE OF THE DISAZO COMPOUNDS AS DYESTUFFS | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-01-30 | — | — | EP | disclosed |
| US-4394310-A | DIAZOTIZATION, CYCLIZATION | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-07-19 | — | — | US | disclosed |
| EP-0071168-A2 | Water-soluble disazo compounds and bis-(amino-phenoxy)-ethane compounds with fibre reactive groups as tetrazo compounds, process for the preparation of these compounds and the use of the disazo compounds as dyestuffs | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-02-09 | — | — | EP | disclosed |
| EP-0047863-A2 | Reactive phthalocyanine hyes, process for their preparation and their use in dyeing materials containing hydroxyle groups and/or nitrogen | BAYER AG (DE) | 1982-03-24 | — | — | EP | disclosed |
| US-4126609-A | AZO DYESTUFF WITH A FIBER-REACTIVE GROUP ATTACHED TO A NAPHTHALENE SULPHONIC ACID COMPONENT | BAYER AKTIENGESELLSCHAFT (DE) | 1978-11-21 | — | — | US | disclosed |
| US-4049704-A | AZO REACTIVE DYES | BAYER AKTIENGESELLSCHAFT (DT) | 1977-09-20 | — | — | US | disclosed |
| US-3958933-A | Process for the manufacture of fast dyeings on synthetic hydrophobic textile material | CIBA-GEIGY CORPORATION (US) | 1976-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509441-B2 | Compounds used as kinase inhibitors and application thereof | ERBB2, ERBB3, BRAF | KEAP1 2450/4885NFE2L2 1623/4885NFKB1 4126/4885 |
| US-12129237-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | MAP3K2, HDGF, MAP3K1 | KEAP1 30/4885NFE2L2 50/4885NFKB1 483/4885 |
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | KEAP1 801/4885NFE2L2 2095/4885NFKB1 1078/4885 |
| US-20250115597-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | TYK2, JAK2, JAK1 | KEAP1 1406/4885NFE2L2 3065/4885NFKB1 1884/4885 |
| US-12129250-B2 | TYK2 inhibitors and compositions and methods thereof | TYK2, JAK2, JAK1 | KEAP1 1406/4885NFE2L2 3065/4885NFKB1 1884/4885 |
| US-12168009-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SLC26A4 | KEAP1 801/4885NFE2L2 2095/4885NFKB1 1078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.